Takeda Pharmaceutical Co. Ltd.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed February 13, 2025), Takeda Pharmaceutical Co. Ltd. reported 15 stock positions worth $289.0 million. Its top holding was Hillevax (HLVX) at 38.7% of the portfolio, followed by Denali Therapeutics (DNLI, 29.9%) and Phathom Pharmaceuticals (PHAT, 11.6%). Compared with Q4 2023, it opened 1 new position and reduced 2. The biggest buy was a new position in Day One Biopharmaceuticals I (DAWN) and the biggest sale Phathom Pharmaceuticals (PHAT, shares −58%).
- Most Recent 13F
- Q3 2025
- Location
- Tokyo, M0
- CIK
- 0001395064
- Portfolio Value
- $289.0M (Q1 2024)
- SEC Filing
- 0001395064-25-000026 ↗ filed Feb 13, 2025
Holdings Value
Holdings 15 stocks · $289.0M
| HLVX Hillevax Inc. | 38.69% | 6,724,000 | $111.8M | No change |
| DNLI Denali Therapeutics Inc. | 29.92% | 4,214,559 | $86.5M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 11.59% | 3,153,217 | $33.5M | Reduce -57.7% |
| OVID Ovid Therapeutics Inc. | 7.95% | 7,531,996 | $23.0M | No change |
| STTK Shattuck Labs Inc. | 4.64% | 1,501,061 | $13.4M | Reduce -28.2% |
| WVE Wave Life Sciences Ltd. | 2.88% | 1,346,892 | $8.3M | No change |
| EQ Equillium Inc. | 1.46% | 1,824,977 | $4.2M | No change |
| TSBX Turnstone Biologics Corp. | 0.81% | 895,824 | $2.3M | No change |
| XLO Xilio Therapeutics Inc. | 0.55% | 1,475,121 | $1.6M | No change |
| DAWN Day One Biopharmaceuticals I | 0.49% | 85,840 | $1.4M | New |
| AMWL American Well Corp. Class A | 0.44% | 1,554,669 | $1.3M | No change |
| RANI Rani Therapeutics Holdings Class A | 0.36% | 338,679 | $1.1M | No change |
| AEROVATE THERAPEUTICS INC | 0.14% | 13,580 | $402K | No change |
| AKLI Akili Inc. | 0.07% | 738,819 | $214K | No change |
| LAB Standard Biotools Inc. | 0.02% | 16,515 | $45K | No change |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
| DAWN Day One Biopharmaceuticals I | New | 0.49% | +0.49 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 8 | $16.4M | OVID, EQ, XLO, STTK, LYEL |
| Q2 2025 | 11 | $19.6M | HLVX, OVID, XLO, AMWL, EQ |
| Q1 2025 | 11 | $16.2M | HLVX, OVID, XLO, EQ, AMWL |
| Q4 2024 | 11 | $26.6M | HLVX, OVID, XLO, EQ, STTK |
| Q3 2024 | 10 | $38.0M | HLVX, WVE, OVID, STTK, EQ |
| Q2 2024 | 13 | $232.3M | DNLI, HLVX, PHAT, WVE, OVID |
| Q1 2024 | 15 | $289.0M | HLVX, DNLI, PHAT, OVID, STTK |